Application of a Physiologically Based Pharmacokinetic Model to Predict Cefazolin and Cefuroxime Disposition in Obese Pregnant Women Undergoing Caesarean Section
Open Access
- 30 May 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (6) , 1162
Abstract
Intravenous (IV) cefuroxime and cefazolin are used prophylactically in caesarean sections (CS). Currently, there are concerns regarding sub-optimal dosing in obese pregnant women compared to lean pregnant women prior to CS. The current study used a physiologically based pharmacokinetic (PBPK) approach to predict cefazolin and cefuroxime pharmacokinetics in obese pregnant women at the time of CS as well as the duration that these drug concentrations remain above a target concentration (2, 4 or 8 µg/mL or µg/g) in plasma or adipose tissue. Cefazolin and cefuroxime PBPK models were first built using clinical data in lean and in obese non–pregnant populations. Models were then used to predict cefazolin and cefuroxime pharmacokinetics data in lean and obese pregnant populations. Both cefazolin and cefuroxime models sufficiently described their total and free levels in the plasma and in the adipose interstitial fluid (ISF) in non–pregnant and pregnant populations. The obese pregnant cefazolin model predicted adipose exposure adequately at different reference time points and indicated that an IV dose of 2000 mg can maintain unbound plasma and adipose ISF concentration above 8 µg/mL for 3.5 h post dose. Predictions indicated that an IV 1500 mg cefuroxime dose can achieve unbound plasma and unbound ISF cefuroxime concentration of ≥8 µg/mL up to 2 h post dose in obese pregnant women. Re-dosing should be considered if CS was not completed within 2 h post cefuroxime administration for both lean or obese pregnant if cefuroxime concentrations of ≥8 µg/mL is required. A clinical study to measure cefuroxime adipose concentration in pregnant and obese pregnant women is warranted.Keywords
Funding Information
- Royal Embassy of Saudi Arabia, cultural Bureau in London
This publication has 65 references indexed in Scilit:
- A pregnancy physiologically based pharmacokinetic (p‐PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4British Journal of Clinical Pharmacology, 2012
- Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal PregnancyClinical Pharmacokinetics, 2012
- Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese PatientsClinical Pharmacokinetics, 2011
- Effects of Maternal Obesity on Tissue Concentrations of Prophylactic Cefazolin During Cesarean DeliveryObstetrics & Gynecology, 2011
- Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimensExpert Review of Pharmacoeconomics & Outcomes Research, 2010
- Protein binding of cefazolin is saturable in vivo both between and within patientsBritish Journal of Clinical Pharmacology, 2007
- A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal functionBritish Journal of Clinical Pharmacology, 2006
- Comparison of the Pharmacokinetics of Cephradine and Cefazolin in Pregnant and Non-Pregnant WomenClinical Pharmacokinetics, 1987
- CEFUROXIME: POTENTIAL USE IN PREGNANT WOMEN AT TERMBJOG: An International Journal of Obstetrics & Gynaecology, 1981
- Kidney transport of cefazolin in normal and impaired renal functionJournal of Antimicrobial Chemotherapy, 1977